Further to its bulletin dated March 13, 2026, the Toronto Stock Exchange reports that it has extended its review of the eligibility of the Class A common shares of Appili Therapeutics Inc. for continued listing for a period of 30 days.
© 2026 Canjex Publishing Ltd. All rights reserved.